GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression (Q45098997)

9 December 2017

GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression (English)

1 reference

9 December 2017

1 reference

1

Eléonore Beurel

1 reference

9 December 2017

Michel Kornprobst

2

1 reference

9 December 2017

Marie-José Blivet-Van Eggelpoël

3

1 reference

9 December 2017

Carmen Ruiz-Ruiz

4

1 reference

9 December 2017

Axelle Cadoret

5

1 reference

9 December 2017

Jacqueline Capeau

6

1 reference

9 December 2017

Christèle Desbois-Mouthon

7

1 reference

9 December 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

Experimental Cell Research

9 December 2017

1 reference

9 December 2017

300

1 reference

9 December 2017

2

1 reference

9 December 2017

354-364

1 reference

Search for a common mechanism of mood stabilizers.

9 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Mood stabilizers, glycogen synthase kinase-3beta and cell survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

GSK3 takes centre stage more than 20 years after its discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

GSK-3beta phosphorylation and alteration of beta-catenin in hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Cyclin D1 over-expression correlates with beta-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3 beta and ERK1/2 in mouse hepatic carcinogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Expression, localization, and activity of glycogen synthase kinase 3beta during mouse skin tumorigenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3-kinase activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Glycogen Synthase Kinase-3β (GSK3β) Binds to and Promotes the Actions of p53

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Death and anti-death: tumour resistance to apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Characterization of p53-mediated up-regulation of CD95 gene expression upon genotoxic treatment in human breast tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Shared pathways: death receptors and cytotoxic drugs in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

The role of Fas and FasL as mediators of anticancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Checkpoints: How to activate p53

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Effects of psychotropic drugs on cell proliferation and differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Wnt signaling to beta-catenin involves two interactive components. Glycogen synthase kinase-3beta inhibition and activation of protein kinase C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Enhanced phosphorylation of p53 by ATM in response to DNA damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Activation of the ATM kinase by ionizing radiation and phosphorylation of p53

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Regulation of Fas expression by STAT3 and c-Jun is mediated by phosphatidylinositol 3-kinase-AKT signaling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.08.001

10.1016/J.YEXCR.2004.08.001

7 January 2021

Identifiers

DOI

1 reference

9 December 2017

1 reference